ArticleNeuron2013
Anti-tau antibodies: hitting the target.
Article in Neuron, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures.Cells · 2025Review
- A short perspective on the long road to effective treatments for Alzheimer's disease.British journal of pharmacology · 2019Review
- Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade.Molecular neurodegeneration · 2019Article
- rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies.The Journal of experimental medicine · 2019Article
- The Role of Tau Imaging in Parkinsonian Disorders.Current neurology and neuroscience reports · 2018Review
- Article
- Frontotemporal dementia: latest evidence and clinical implications.Therapeutic advances in psychopharmacology · 2018Review
- Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies.Molecular neurobiology · 2016Review
- New Features about Tau Function and Dysfunction.Biomolecules · 2016Review
- The role of extracellular Tau in the spreading of neurofibrillary pathology.Frontiers in cellular neuroscience · 2014Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapies targeting tau in mouse models of human tauopathies could have disease-modifying effects. In this issue of Neuron, Yanamandra et al. (2013) use tau antibodies, which effectively block tau seeding in culture, to attenuate tauopathy and improve cognition in mutant tau mouse models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.